Second medical use: a regulatory perspective
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
Latest news
Senator calls on Biden to reject COVID IP waiver
02-03-2021
Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Five minutes with… Eva Kabir
02-03-2021
Cutting back the thickets of Biosimilars
01-03-2021
Regions
Sectors
- Second medical use: a regulatory perspective 08-02-2021
- The importance of Minerva Surgical v Hologic 02-02-2021
